Clinical Trial Update: Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating radiation plus durvalumab as neoadjuvant therapy for bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Bladder Cancer | Phase 2 | Status: UNKNOWN